What is the common way to take filgotinib in patients?

Filgotinib(Filgotinib) is currently approved for the treatment of active rheumatoid arthritis and other chronic inflammatory diseases in European and American countries and some Asian markets such as Japan. This drug is an oral preparation and is easy to take. It is one of the important choices for many patients who need long-term medication. Its standard usage is mainly to take it orally once a day to facilitate patients' continuous treatment and improve compliance.

In most clinical practices, the recommended dose of filgotinib is 200 mg once daily. For some special groups, such as patients with renal insufficiency, impaired liver function, or patients with a higher risk of infection, doctors may adjust the dose to 100 mg once daily based on specific circumstances. In addition, when combined with other immunomodulatory drugs, such as with methotrexate (MTX), dosing usually remains on a once-daily basis to reduce the risk of potential drug interactions.

It is recommended to swallow the medicine with water, regardless of whether you eat or not. However, for the comfort of the gastrointestinal tract, some doctors may recommend that patients take it with food to reduce the risk of gastrointestinal side effects. It is important to note that filgotinib is a long-term drug, and its efficacy is not immediate. Most patients will not notice significant improvement in symptoms such as joint pain and swelling until several weeks to months later, so adherence to regular medication is the key to successful treatment.

During long-term medication, liver function, kidney function, blood cell count and other indicators should be monitored regularly to ensure medication safety and avoid serious complications due to drug accumulation or immunosuppression. At the same time, it is also recommended that patients undergo screening for potential infections before taking medication, especially screening for viral infections such as tuberculosis and hepatitis B, to prevent infection activation after the immune system is suppressed.

Reference materials:https://go.drugbank.com/drugs/DB14845